VERONICA EMHOLTZ: Open Payments
NPI 1548595937 · HOUSTON, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$729 in 35 payments from 16 companies in 2025. Trend: 2023 $1,812 · 2024 $808 · 2025 $729
Food & beverage: $729
| Company | Payments | Amount |
|---|---|---|
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 6 | $107 |
| Intercept Pharmaceuticals, Inc. | 4 | $80 |
| Gilead Sciences, Inc. | 4 | $77 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $59 |
| Ipsen Biopharmaceuticals, Inc | 3 | $59 |
| Novo Nordisk Inc | 3 | $59 |
| Mallinckrodt Hospital Products Inc. | 2 | $51 |
| ORPHALAN INC | 2 | $48 |
| Madrigal Pharmaceuticals | 2 | $38 |
| Merck Sharp & Dohme LLC | 1 | $34 |
Products named: XIFAXAN, OCALIVA, LIVTENCITY, IQIRVO, TERLIVAZ, CUVRIOR, REZDIFFRA, Wegovy.
Industry payments across TX — which companies pay providers there.
